par Schöffski, Patrick;Awada, Ahmad ;Dumez, Herlinde;Gil, Thierry ;Bartholomeus, Sylvie;Wolter, P;Taton, Martine ;Fritsch, Holger;Glomb, Patricia;Munzert, Gerd
Référence European journal of cancer, 48, 2, page (179-186)
Publication Publié, 2012-01
Référence European journal of cancer, 48, 2, page (179-186)
Publication Publié, 2012-01
Article révisé par les pairs
Titre: |
|
Auteur: | Schöffski, Patrick; Awada, Ahmad; Dumez, Herlinde; Gil, Thierry; Bartholomeus, Sylvie; Wolter, P; Taton, Martine; Fritsch, Holger; Glomb, Patricia; Munzert, Gerd |
Informations sur la publication: | European journal of cancer, 48, 2, page (179-186) |
Statut de publication: | Publié, 2012-01 |
Sujet CREF: | Cancérologie |
Mots-clés: | Dose escalation |
Phase I | |
Polo-like kinase (Plk) inhibitor | |
Solid tumours | |
Volasertib (BI 6727) | |
MeSH keywords: | Adult |
Aged | |
Antineoplastic Agents -- pharmacokinetics -- therapeutic use | |
Cohort Studies | |
Dose-Response Relationship, Drug | |
Female | |
Half-Life | |
Humans | |
Male | |
Middle Aged | |
Neoplasms -- drug therapy -- metabolism | |
Protein Kinase Inhibitors -- pharmacokinetics -- therapeutic use | |
Pteridines -- pharmacokinetics -- therapeutic use | |
Young Adult | |
Note générale: | Clinical Trial, Phase I |
Journal Article | |
Research Support, Non-U.S. Gov't | |
SCOPUS: ar.j | |
Langue: | Anglais |
Identificateurs: | urn:issn:0959-8049 |
info:doi/10.1016/j.ejca.2011.11.001 | |
info:pii/S0959-8049(11)00874-4 | |
info:scp/84655164874 | |
info:pmid/22119200 |